Original-product discount agreements for vemurafenib 2026-10

Summary

The tender concerns the conclusion of discount agreements for the active substance vemurafenib with all suitable pharmaceutical undertakings under an open-house procedure. Contract terms are standardised and will not be individually negotiated. No exclusivity is guaranteed to any contracting partner. The contract may last for up to 24 months from 1 November 2026 and ends no later than 31 October 2028, regardless of the contract-signing date. If the patent or market exclusivity expires earlier, the contract ends automatically at the end of that month. Eligible companies may join the procedure at any time during the contract period. Further participation and contractual details must be checked in the official documents.